Clear All
727 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9393 Fulvestrant (Teva) Fulvestrant (Teva) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
NA Panobinostat Farydak 15 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
J2505 Pegfilgrastim Neulasta:Neulasta Onpro 6 mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2002 Jan 1, 2004 Jan 26, 2022 No Longer Used
Q5122 Pegfilgrastim-apgf Nyvepria 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2020 Jan 1, 2021 In Use
J9207 ixabepilone Ixempra 1mg Chemotherapy Antitumor Antibiotic Epothilones No 2007 Jan 1, 2009 In Use
NA Avapritinib Ayvakit 50mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA venetoclax Venclexta 10 mg Chemotherapy Enzyme Inhibitor BCL-2 Yes 2016 In Use
C9110 Alemtuzumab Lemtrada 10 mg Immunotherapy Monoclonal Antibody CD52 No 2001 Jan 1, 2001 Dec 31, 2007 No Longer Used
NA Axitinib Axitinib 1 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
Capivasertib Truqap 160mg, 200mg Chemotherapy AKT Inhibitor AKT 1/2/3 Yes 2023 In Use
NA Anastrozole Arimidex 0.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1995 In Use
J9059 Bendamustine (Baxter) Bendamustine (Baxter) 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2022 Jul 11, 2023 In Use
J9057 Copanlisib Aliqopa 1mg Chemotherapy Enzyme Inhibitor PI3K No 2017 In Use
Q2050 Doxorubicin Doxil 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1995 Jul 1, 2013 In Use
Fruquintinib Fruzaqla 1mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2023 In Use
J9022 Atezolizumab Tecentriq 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2016 Jan 1, 2018 In Use
C9084 Loncastuximab tesirine Zylonta 0.1mg Immunotherapy Drug Antibody Conjugate CD19 No 2021 Sep 27, 2021 Mar 25, 2022 In Use
C9449 Blinatumomab Blincyto 1 mcg Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) No 2014 Apr 1, 2015 In Use
NA Avapritinib Ayvakit 25mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
Q2041 Axicabtagene Ciloleucel Yescarta Up to 200 million Immunotherapy CAR-T CD19 No 2017 Jan 1, 2019 In Use
NA Aprepitant Emend 80 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
C9012 Arsenic Trioxide Trisenox unspecified Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan 1, 2001 Dec 31, 2001 No Longer Used
J9037 Belantamab mafodontin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Apr 1, 2021 In Use
J9020 Asparaginase Erwinaze 10, 000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 1994 Jan 1, 1984 In Use
C9069 Belantamab mafodotin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Jan 1, 2021 No Longer Used
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.